8-K: InnovAge Reports Strong FY25 Revenue Growth, Improved Profitability

InnovAge Holding Corp. announced robust financial results for fiscal year 2025, driven by significant revenue growth and improved Adjusted EBITDA, alongside increased participant census.

Summary

• Total revenues for fiscal year 2025 reached $853.7 million, an 11.8% increase from $763.9 million in fiscal year 2024.
• Net loss for fiscal year 2025 was $35.3 million, an increase of 52% compared to a net loss of $23.2 million in fiscal year 2024.
• Adjusted EBITDA for fiscal year 2025 increased by $18.0 million to $34.5 million, up from $16.5 million in fiscal year 2024, with Adjusted EBITDA margin improving to 4.0% from 2.2%.
• Center-level Contribution Margin grew by 16.3% to $153.6 million in fiscal year 2025, compared to $132.1 million in fiscal year 2024.
• Participant census increased to approximately 7,740 participants as of June 30, 2025, up from 7,020 participants in 2024.
• The company provided fiscal year 2026 guidance, projecting total revenues between $900 million and $950 million, and Adjusted EBITDA between $56 million and $65 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong operational performance, including significant growth in revenue, Adjusted EBITDA, and participant census, coupled with a positive outlook for the next fiscal year. The shift to positive operating cash flow is a strong indicator. However, the increased GAAP net loss due to substantial one-time charges for litigation and asset impairments tempers the overall positive sentiment.

Positives

• Total revenues increased by 11.8% to $853.7 million for fiscal year 2025.
• Adjusted EBITDA significantly increased by $18.0 million to $34.5 million, representing a 109% year-over-year growth.
• Adjusted EBITDA margin improved by 1.9 percentage points to 4.0% for fiscal year 2025.
• Center-level Contribution Margin increased by 16.3% to $153.6 million, with its margin improving by 0.7 percentage points to 18.0%.
• Participant census grew to 7,740, an increase of 720 participants from the prior year, indicating strong program enrollment.
• Net cash provided by operating activities was $32.866 million for fiscal year 2025, a significant improvement from net cash used in operating activities of $36.898 million in fiscal year 2024.
• Fiscal year 2026 guidance projects continued growth in revenues and Adjusted EBITDA.

Negatives

• Net loss increased by 52% to $35.3 million for fiscal year 2025, compared to $23.2 million in fiscal year 2024.
• Loss Before Income Taxes increased by 56.0% to $34.0 million for fiscal year 2025, compared to $21.8 million in fiscal year 2024.
• Net loss per share increased to $0.22 for fiscal year 2025, up from $0.16 per share in fiscal year 2024.
• Significant litigation costs and settlement charges of $19.367 million were incurred for the year ended June 30, 2025, including $10.1 million accrued for a potential stockholder class action settlement.
• Asset impairments and loss on assets held for sale totaled $13.615 million for fiscal year 2025, primarily due to halting development of a planned de novo center in Louisville, Kentucky.
• Loss on cost and equity method investments was $1.393 million for fiscal year 2025, including a $2.6 million impairment loss for an investment in DispatchHealth Holdings Inc.

Risks

• The viability of the growth strategy, including the ability to find suitable geographies for new centers, attract and retain participants, and obtain necessary licenses.
• The ability to identify, successfully complete, and integrate acquisitions, joint ventures, and other strategic partnerships.
• Impacts from ongoing macroeconomic challenges such as labor shortages, labor competition, inflation, tariffs, and trade disputes.
• Inspections, reviews, audits, and investigations under federal and state government programs, and the ability to sufficiently cure any identified deficiencies.
• Legal proceedings, enforcement actions, litigation, and disputes, which are costly to defend.
• Assuming all risk under PACE contracts where the cost of providing services may exceed compensation.
• Dependence of revenues upon a limited number of government payors, including the risk of sudden loss of any government contracts.
• The impact of state and federal efforts to reduce healthcare spending, including recent legislation reducing the budget that funds Medicaid.
• The risk that submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, potentially subjecting the company to repayment obligations or penalties.
• The ability to comply with the continued listing requirements of Nasdaq.

Future Outlook

For fiscal year 2026, InnovAge expects participant census to be between 7,900 and 8,100, with total member months ranging from 91,600 to 94,400. Total revenues are projected to be between $900 million and $950 million, and Adjusted EBITDA is guided to be between $56 million and $65 million.

Management Comments

• "Fiscal 2025 was a strong year. The combination of responsible growth, financial discipline, clinical performance, and compliance execution is what gives us confidence in the durability of our progress."
• "We expect Fiscal 2026 to continue that momentum."

Industry Context

InnovAge operates as a market leader in the Program of All-inclusive Care for the Elderly (PACE), a specialized healthcare model for frail, predominantly dual-eligible seniors. The reported growth in participant census and improved operational metrics like Adjusted EBITDA and Center-level Contribution Margin suggest effective execution within this niche, patient-centered care model, which aims to improve care quality and reduce the utilization of high-cost care settings. The positive outlook for FY2026 indicates confidence in continued expansion and operational efficiency within the growing senior care market.

Legal Proceedings

• Incurred $19.367 million in litigation costs and settlements for the year ended June 30, 2025, including $10.1 million accrued for the potential settlement of a previously disclosed stockholder class action.
• Incurred costs related to litigation concerning a de novo center and civil investigative demands.

Stakeholder Impact

• Shareholders: Positive operational performance and future guidance could lead to increased investor confidence, despite increased GAAP losses due to one-time charges. Litigation costs and asset impairments represent a drain on shareholder value.
• Participants: Increased census indicates successful outreach and service delivery to more seniors, aligning with the mission to enable independent aging.
• Government Payors: The PACE model aims to reduce high-cost care settings, potentially benefiting government payors through more efficient healthcare delivery.
• Employees: Business optimization initiatives and organizational restructuring mentioned in the non-GAAP reconciliation could impact employees.

Next Steps

• Host a conference call on September 9, 2025, at 5:00 p.m. Eastern Time to discuss the financial results.

Key Dates

Recommendation

InnovAge demonstrated strong underlying operational performance in fiscal year 2025, with robust revenue growth, a significant increase in Adjusted EBITDA, and a healthy expansion of its participant census. The company's shift to positive operating cash flow is a critical indicator of improving financial health and sustainability. While the reported net loss increased, this was primarily driven by substantial, non-recurring charges related to litigation and asset impairments, which are not indicative of the core business's ongoing profitability. The positive financial guidance for fiscal year 2026 further reinforces confidence in the company's growth trajectory and operational efficiency within the specialized PACE market. These factors suggest a strong outlook for the company's intrinsic value, making it an attractive investment.

Keywords

InnovAge, PACE, senior care, healthcare programs, financial results, fiscal year 2025, Adjusted EBITDA, revenue growth, participant census, Q4 2025, Nasdaq